Customer Center
Login | Register

VERIGENE® Gram-Positive Blood Culture Test

VERIGENE® Bloodstream Infection Tests | VERIGENE® Gram-Positive Blood Culture Test

Identify genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles

While conventional microbiological methods may require 2-4 days to produce bacterial identification and susceptibility results, VERIGENE BC-GP provides results within 2.5 hours of blood culture positivity.

 

Gram-positive bacteria are also a common source of contamination during blood draws, which results in clinically-irrelevant positive blood cultures. This can lead to inappropriate antimicrobial use1 and wasted time and cost. Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods.

Gram-Positive Blood Culture Test Specifications

 

Targets U.S./FDA-Cleared Outside U.S.
Species
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus anginosus Group
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium
Genus
Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.  
Listeria spp.
Resistance
mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)

 

Key Features
Automation Sample to Result
Instrumentation VERIGENE Reader and Processor SP
Workflow On-Demand and Scalable
Sample Type Positive Blood Culture Bottle
Hands-On Time <5 minutes
Run Time <2.5 hours
†For use with all commercially available continuous monitoring blood culture bottles; see VERIGENE BC-GP package insert for details.

 

 

Ordering information for VERIGENE® Gram-Positive Blood Culture Test

 

Luminex Online Order Management
Email: [email protected]
Phone: 1-512-336-3550
Toll Free: 1-866-401-5450
Fax: 1-512-219-0544
Fax (Europe, Middle East, India, Asia): +31 (0)73 800 1998
Product Name Kit Size Registration
Status
Part Number
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Kit 20 BC-GP Test Cartridges
20 Extraction Trays
US-IVD
CE Marked
20-005-018
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Utility Reagent Kit

20 BC-GP Utility Trays US-IVD
CE Marked
20-012-018
VERIGENE® Sample Processor SP 1 unit US-IVD
CE Marked
10-0000-07
VERIGENE® Reader 1 unit US-IVD
CE Marked
10-0000-02

 

Resources

 

VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IVD)Product Information


Each Hour Counts: The Clinical and Economic Case for Rapid Sepsis DiagnosticsWebinar


Each Hour Counts: Optimizing Therapy for Bloodstream Infections with Rapid Molecular TestingWebinar


Each Hour Counts: Improving Management of CRE’s and Other Antibiotic-Resistant BSI’s with Rapid Molecular DiagnosticsWebinar


Each Hour Counts: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture TestingWebinar


In Their Own Words: Dr. Neelam Dhiman at med fusion & Clearpoint Diagnostic LaboratoriesWebinar


Justification, Validation and Implementation Best Practices for Multiplex Molecular Infectious Disease TestsWebinar


Impact of Rapid Molecular Testing of Gram-Positive Blood Culture Isolates Using VERIGENE Gram-Positive Blood Culture on Antimicrobial Stewardship and Clinical Outcomes within a Community Health SystemPoster


Results of Rapid Identification of Gram-Positive Bacteria combined with Rapid Pharmacy Notification and Treatment in a Community Hospital Healthcare SystemPoster


Impact of Integrating the VERIGENE Gram-Positive Blood Culture (BC-GP) Test with Antimicrobial Stewardship in a Non-Teaching Community HospitalPoster


Outcomes Utilizing Rapid Diagnostic Technology Coupled with Pharmacist Intervention in Patients with Gram-Positive Bloodstream InfectionsPoster


Outcomes of Rapid Identification for Gram-Positive Bacteremia in Combination with Antibiotic Stewardship at a Community-Based Hospital SystemArticle


Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric HospitalArticle


Evaluation Of The VERIGENE GN-BC For The Identification Of Gram Negative Bacilli And Detection Of Antibiotic Resistance Mechanisms Directly From Positive Blood CulturesAbstract


Comparison of VERIGENE BC-GP to Peptide Nucleic Acid Fluorescence in situ Hybridization (PNA-FISH) in Conjunction with mecA Gene Detection for Staphylococcus aureus BacteremiaAbstract


De-escalation of Antibiotics in Response to the VERIGENE Gram-Positive Blood Culture AssayAbstract


Effects of Blood Volume on the Performance of the VERIGENE BC-GP Assay in Pediatric PatientsAbstract


Implementation and Accuracy of Rapid Molecular Diagnostics in Sepsis: Recipe for SUCCESSAbstract


Accuracy and Potential Clinical Utility of Two Rapid Molecular Panels for Detection of Bloodstream InfectionAbstract


Impact of the VERIGENE Gram-Positive Blood Culture Assay in a Tertiary Care Pediatric HospitalAbstract


Rapid Diagnosis of Sepsis Using VERIGENE BC-GP and BC-GN Test: A Multicenter Evaluation in Hong KongAbstract


Outcomes Utilizing Pharmacist Intervention and Rapid Molecular Diagnostic Technology (RMDT) in Patients with Gram-Positive Bloodstream Infections (BSI)Abstract


Comparison Between VERIGENE BC-GP And PNA-FISH Testing on the Treatment of Staphylococcus-related Blood Stream Infections (BSI)Abstract


Impact of a Rapid Molecular Diagnostic Test and Antimicrobial Stewardship on Time to Optimal Therapy in Bacteremic PatientsAbstract


Antimicrobial Stewardship and the Use of VERIGENE Gram-Positive and Gram-Negative Rapid Identification SystemAbstract


Improved Clinical Outcomes after Implementation of Molecular Detection of Blood Culture ContaminantsAbstract


Impact of Rapid Molecular Testing of Gram-Positive Blood Culture Isolates Using VERIGENE Gram-Positive Blood Culture (BC-GP) on Antimicrobial Stewardship and Clinical Outcomes within a Community Health SystemAbstract


Experience with Rapid Diagnostic Technology and Antimicrobial Stewardship for Patients with Gram-positive Bloodstream InfectionsAbstract


Development and Implementation of a Treatment Algorithm for Gram-Positive Bloodstream Infections Identified by a Gram-Positive Nucleic Acid Microarray AssayAbstract


Screening on Non-Blood Culture Isolates for Multi-Drug Resistance using the VERIGENE SystemAbstract


Misidentification of a Bloodstream Klebsiella variicola Infection: An Investigation in Laboratory DiagnosisAbstract


Challenges of Antimicrobial Stewardship at a Community Hospital using Rapid Identification Methods for Gram Positive BacteremiaAbstract

VERIGENE® BLOODSTREAM INFECTION TESTS

Learn how the VERIGENE® System provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.
 
Read More

GRAM-NEGATIVE BLOOD CULTURE TESTS

Learn how the VERIGENE Gram-Negative Blood Culture Test (BC-GN) can provide results within two hours of blood culture positivity.
 
 
Read More

  1. von Eiff C, Herrmann M, Peters G. 1995. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Ag Chemo. 39:268-270.

 

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result VERIGENE System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.

BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, Listeria spp.

In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureus or S. epidermidis.

BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.